AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

Executive Summary: AZD0156 (APExBIO B7822) is an orally bioavailable, potent, and highly selective inhibitor of ataxia telangiectasia mutated (ATM) kinase, a key regulator in the DNA damage response pathway (APExBIO). The compound demonstrates sub-nanomolar inhibition of ATM signaling and over 1000-fold selectivity over other PIKK family kinases (Huang et al. 2023). AZD0156 enhances antitumor efficacy of DNA-damaging agents in preclinical cancer models and is currently in early-phase clinical trials for advanced cancers. Mechanistic studies reveal that ATM inhibition by AZD0156 induces metabolic adaptation, including increased macropinocytosis, highlighting new therapeutic vulnerabilities in cancer biology (Huang et al. 2023). Rigorous analytical validation (HPLC, NMR) confirms purity ≥98% under specified storage conditions.

Biological Rationale

ATM kinase belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) family and orchestrates the cellular response to DNA double-strand breaks (DSBs) (Huang et al. 2023). Upon DSBs, ATM activates checkpoint control, DNA repair, and maintains genomic stability. Loss or inhibition of ATM results in impaired DNA repair, increased genomic instability, and altered cellular metabolism (Huang et al. 2023). In cancer, ATM is often mutated or downregulated, predisposing cells to tumorigenesis and influencing therapeutic responses. Selective ATM inhibitors like AZD0156 enable precise interrogation and modulation of these pathways in cancer research.

Mechanism of Action of AZD0156

AZD0156 is a small-molecule inhibitor specifically designed to target ATM kinase activity. The compound binds the ATP-binding site of ATM, blocking phosphorylation of downstream targets involved in DNA repair and checkpoint signaling. Inhibition is highly selective: AZD0156 demonstrates over 1000-fold selectivity for ATM versus other PIKK family kinases, including ATR and DNA-PKcs (Huang et al. 2023). Cellular studies confirm sub-nanomolar potency against ATM-driven signaling. ATM inhibition by AZD0156 impairs DNA double-strand break repair, disrupts checkpoint control, and induces metabolic reprogramming characterized by enhanced macropinocytosis and increased amino acid uptake. These effects are particularly relevant in nutrient-poor tumor microenvironments (Huang et al. 2023).

Evidence & Benchmarks

• AZD0156 inhibits ATM kinase with sub-nanomolar potency in cellular assays (IC₅₀ < 1 nM) (APExBIO).
• Compound shows >1000-fold selectivity for ATM over ATR and DNA-PKcs, as measured by comparative biochemical kinase assays (Huang et al. 2023).
• In preclinical cancer models, oral AZD0156 potentiates the antitumor efficacy of DNA double-strand break-inducing agents such as topoisomerase inhibitors (Huang et al. 2023).
• ATM inhibition by AZD0156 drives metabolic adaptation in cancer cells, increasing macropinocytosis and BCAA uptake under nutrient-limited conditions (Huang et al. 2023).
• Combined inhibition of ATM and macropinocytosis suppresses cancer cell proliferation and induces cell death both in vitro and in vivo (Huang et al. 2023).

This article extends prior syntheses on metabolic vulnerabilities revealed by AZD0156 by updating with recent mechanistic data on macropinocytosis and nutrient scavenging. It also clarifies benchmarking criteria discussed in the AZD0156 mechanism and evidence dossier by providing explicit quantitative potency and selectivity data. For broader clinical and workflow context, readers can compare with application-focused summaries, which this article updates with recent clinical trial progress and metabolic findings.

Applications, Limits & Misconceptions

AZD0156 is a research tool for interrogating the DNA damage response, checkpoint control, and metabolic adaptation in cancer models. Its high selectivity benefits studies where off-target PIKK inhibition would confound interpretation. AZD0156 is especially valuable in combination with DNA-damaging agents, enabling preclinical evaluation of synthetic lethality strategies. Early clinical trials are evaluating its safety and efficacy in patients with advanced solid tumors (Huang et al. 2023).

Common Pitfalls or Misconceptions

• AZD0156 is not effective in water-based media due to insolubility; use DMSO or ethanol for stock solutions.
• It should not be assumed that all ATM-deficient tumors will respond to AZD0156; efficacy depends on context, such as p53 and c-MYC status (Huang et al. 2023).
• AZD0156 does not inhibit other PIKK kinases (e.g., ATR, DNA-PKcs) at relevant concentrations; do not extrapolate findings to pan-PIKK inhibition.
• Long-term storage of AZD0156 solutions is not recommended; compound degradation may affect experimental outcomes.
• ATM inhibition can induce metabolic rewiring, so secondary metabolic effects must be considered in data interpretation.

Workflow Integration & Parameters

For in vitro work, AZD0156 should be solubilized in DMSO at ≥23.1 mg/mL or ethanol at ≥5.49 mg/mL with gentle warming. For in vivo or cell-based assays, dilute in compatible solvents immediately prior to use. Store solid compound at -20°C; avoid repeated freeze-thaw cycles and prolonged solution storage. Analytical validation by HPLC and NMR confirms purity ≥98% as provided by APExBIO. ATM inhibition can be confirmed by measuring phosphorylation status of canonical ATM targets (e.g., Chk2, p53) after DNA damage induction. For combination studies, titrate AZD0156 to achieve sub-nanomolar ATM inhibition while monitoring for off-target or metabolic effects. Refer to the AZD0156 product page for full handling and QC details.

Conclusion & Outlook

AZD0156 is a rigorously validated, highly selective ATM kinase inhibitor that enables advanced research in DNA damage response, checkpoint modulation, and metabolic adaptation in cancer. The compound's potency, specificity, and oral bioavailability make it a leading tool in both preclinical and translational oncology studies. Ongoing clinical trials and mechanistic research continue to refine its application, revealing novel therapeutic vulnerabilities and informing rational combination strategies. For detailed protocols, storage, and analytical validation, consult APExBIO and recent peer-reviewed studies (Huang et al. 2023).